IQVIA (NYSE:IQV) Reaches New 52-Week Low - Should You Sell?

Shares of IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) reached a new 52-week low during trading on Wednesday . The company traded as low as $179.12 and last traded at $180.49, with a volume of 637977 shares traded. The stock had previously closed at $181.39.

Analysts Set New Price Targets

A number of brokerages have issued reports on IQV. Stifel Nicolaus cut their price target on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. BTIG Research downgraded IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Truist Financial reiterated a "buy" rating and set a $263.00 price target (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. UBS Group reduced their price objective on IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Finally, Stephens began coverage on IQVIA in a research report on Friday, December 20th. They issued an "overweight" rating and a $250.00 target price on the stock. Five investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of "Moderate Buy" and an average target price of $249.05.

IQVIA Price Performance

The stock has a 50 day moving average price of $193.15 and a two-hundred day moving average price of $206.27. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a market capitalization of $31.25 billion, a price-to-earnings ratio of 23.64, a PEG ratio of 1.99 and a beta of 1.50.

Remove Ads

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Institutional Trading of IQVIA

Several hedge funds have recently added to or reduced their stakes in the company. Synergy Asset Management LLC purchased a new position in IQVIA in the fourth quarter valued at $33,000. GKV Capital Management Co. Inc. acquired a new stake in shares of IQVIA during the 4th quarter worth about $39,000. Lee Danner & Bass Inc. purchased a new stake in IQVIA during the fourth quarter worth approximately $44,000. Zions Bancorporation N.A. raised its holdings in IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after purchasing an additional 85 shares in the last quarter. Finally, Versant Capital Management Inc lifted its position in shares of IQVIA by 46.0% during the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after buying an additional 93 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.